Drug
Zanubrutinib clinical trials
Also written BGB-3111 and Brukinsa.
Keep track of what changes. Save the zanubrutinib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
- Brukinsa
- 49
Studies by the year they started
148 studies that test it; most in 2024 (25); 1 more planned to start later
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2016 | 5 |
| 2017 | 8 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 14 |
| 2021 | 10 |
| 2022 | 22 |
| 2023 | 18 |
| 2024 | 25 |
| 2025 | 23 |
| 2026 | 14 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 13
Who runs them
Industry 40 · Other 109
BeiGene (30) · Institute of Hematology & Blood Diseases Hospital, China (11) · Ruijin Hospital (10) · BeOne Medicines (7) · Peking University People's Hospital (5) · The First Affiliated Hospital of Soochow University (5) · Peking Union Medical College Hospital (5) · City of Hope Medical Center (4)
Often tested with
Tested in the same studies.
Rituximab (32) · Lenalidomide (17) · Obinutuzumab (14) · Sonrotoclax (11) · Bendamustine (9) · Polatuzumab vedotin (7) · Venetoclax (6) · Tislelizumab (5)
Studies
Open first, then newest update. How each study uses zanubrutinib is read from its arms, and is right about nine times in ten.
Testing it · 149
- Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCLRecruitingPhase 2Shanghai Zhongshan HospitalNCT07012980Written as Zanubrutinib
- Sonrotoclax Plus Zanubrutinib in Patients With Relapsed/Refractory Mantle Cell Lymphoma Planned for Standard of Care CAR-T Cell TherapyRecruitingPhase 2Canadian Cancer Trials GroupNCT07341191Written as Zanubrutinib
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingPhase 2SWOG Cancer Research NetworkNCT07638722Written as Zanubrutinib
- A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT06563505Written as Zanubrutinib
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT06350318Written as Zanubrutinib
- A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic LeukemiaRecruitingPhase 3BeOne MedicinesNCT07277231Written as Zanubrutinib
- Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLRecruitingPhase 2Xiaohui RenNCT07839247Written as Zanubrutinib
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingPhase 2Reid Merryman, MDNCT06563596Written as Zanubrutinib
- Zanubrutinib and Tafasitamab in Mantle Cell LymphomaRecruitingPhase 1/2Alvaro Alencar, MDNCT06029309Written as Zanubrutinib
- Zanubrutinib in Combination With Odronextamab for the Treatment of Patients With Richter's TransformationRecruitingPhase 1City of Hope Medical CenterNCT06735664Written as Zanubrutinib
- Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Not yet recruitingPhase 2The Lymphoma Academic Research OrganisationNCT07739459Written as Zanubrutinib
- A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaNot yet recruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT07799220Written as Zanubrutinib
- Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialNot yet recruitingPhase 2City of Hope Medical CenterNCT07812246Written as Zanubrutinib
- ZR-MTX for PIOL Phase II TrialRecruitingPhase 2Peking Union Medical College HospitalNCT06973811Written as Zanubrutinib
- Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WMRecruitingPhase 2Massachusetts General HospitalNCT06561347Written as Zanubrutinib
- Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic LymphomaRecruitingPhase 2Kerry RogersNCT07734038Written as Zanubrutinib
- Zanubritnib and Anti-MAG NeuropathyRecruitingPhase 2Azienda Ospedaliera di PadovaNCT07392229Written as Zanubrutinib Oral Capsule
- Zanubrutinib, Obinutuzumab, Sonrotoclax (BOSon) or BGB-16673, Obinutuzumab, Sonrotoclax (DOSon) in TN CLL/SLLRecruitingPhase 2Massachusetts General HospitalNCT06849713Written as Zanubrutinib
- A Study of Mosunetuzumab Alone or With Zanubrutinib in People With Follicular LymphomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05389293Written as Zanubrutinib
- Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaRecruitingPhase 2Chinese PLA General HospitalNCT06471738Written as Zanubrutinib
See all 149 studies that test zanubrutinib →
Given in every arm · 19 — zanubrutinib is usual care beside what is tested
- Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell LymphomaRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT05976763Written as Zanubrutinib
- Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLLRecruitingPhase 3Alliance for Clinical Trials in OncologyNCT07321652Written as Zanubrutinib
- A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)RecruitingPhase 3BeOne MedicinesNCT06742996Written as Zanubrutinib
- A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.RecruitingPhase 1/2BeOne MedicinesNCT06697184Written as Zanubrutinib
- A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingPhase 1/2BeOne MedicinesNCT06634589Written as Zanubrutinib
- Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment With or Without Sonrotoclax for Patients With Richter TransformationRecruitingPhase 2German CLL Study GroupNCT04271956Written as Zanubrutinib
- AI-Driven Treatment Strategy vs ZR2 in Older Treatment-naive Patients With LBCLNot yet recruitingPhase 2Ruijin HospitalNCT07717177Written as Zanubrutinib
- A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell MalignanciesRecruitingPhase 2Curis, Inc.NCT07271667Written as Zanubrutinib
- BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell LymphomaRecruitingPhase 2Christine RyanNCT06854003Written as Zanubrutinib
- Mosunetuzumab for CLL MRD ClearanceRecruitingPhase 1/2Inhye AhnNCT07052695Written as Zanubrutinib
- Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to TreatmentRecruitingPhase 2SWOG Cancer Research NetworkNCT05890352Written as Zanubrutinib
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)RecruitingPhase 2VA Office of Research and DevelopmentNCT06520098Written as Ibrutinib, Acalabrutinib, Zanubrutinib
- Immunobridging/Maintenance Therapy Versus Non-bridging Therapy in CAR-T Therapy for Low-risk R/R B-NHLRecruitingPhase 2Ruijin HospitalNCT06695013Written as zanubrutinib
- ARTA-based Chemo-free Bridging/Maintenance Therapy in CAR-T Treatment for High-Risk R/R B-NHL Ineligible for HDCT and ASCTNot yet recruitingPhase 2Ruijin HospitalNCT06646666Written as zanubrutinib
- A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibActive, not recruitingPhase 3BeOne MedicinesNCT04170283Written as Zanubrutinib
- A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutinib Alone in Participants With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingPhase 2BeOne MedicinesNCT06637501Written as Zanubrutinib
- Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell MalignanciesActive, not recruitingPhase 1BeOne MedicinesNCT04277637Written as Zanubrutinib
- Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabActive, not recruitingPhase 2Weill Medical College of Cornell UniversityNCT05650723Written as Zanubrutinib Pill
- Zanubrutinib and Rituximab Followed by R-DHAOx Then Maintenance with Zanubrutinib for Newly-Diagnosed MCLActive, not recruitingPhase 2Sun Yat-sen UniversityNCT04624958Written as Zanubrutinib and Rituximab
As the comparator · 4 — what is tested is compared with zanubrutinib
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingPhase 2National Cancer Institute (NCI)NCT04840602Written as Zanubrutinib
- A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaRecruitingPhase 3Guangzhou Lupeng Pharmaceutical Company LTD.NCT07377578Written as Zanubrutinib
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingPhase 3Loxo Oncology, Inc.NCT04662255Written as Zanubrutinib
- A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)CompletedPhase 3BeiGeneNCT03053440Written as BGB-3111
Codes
What other systems call zanubrutinib · ClinicalTrials.gg INT001030
- MeSH (NLM) C000629551zanubrutinibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) AG9MHG098ZZANUBRUTINIBConfirmed FDA, NLM, Wikidata
- RxNorm 2262435One source FDA
- Wikidata Q75192022zanubrutinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C141428ZanubrutinibOne source FDA
- DrugBank DB15035One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629551 | zanubrutinib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | AG9MHG098Z | ZANUBRUTINIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2262435 | — | One source FDA |
| Wikidata | Q75192022 | zanubrutinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C141428 | Zanubrutinib | One source FDA |
| DrugBank | DB15035 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.